<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-88827" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Methylene Blue</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bistas</surname>
            <given-names>Evangelos</given-names>
          </name>
          <aff>Medical University of the Americas</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sanghavi</surname>
            <given-names>Devang K.</given-names>
          </name>
          <aff>Mayo Clinic</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Evangelos Bistas declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Devang Sanghavi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>26</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-88827.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Methylene blue is a medication used in the management and treatment of methemoglobinemia, a condition in which hemoglobin decreases its ability to carry oxygen. This activity reviews the indications, action, adverse effects, and contraindications for methylene blue as a valuable agent in the therapy of methemoglobinemia, vasoplegic syndrome,<italic toggle="yes"> Plasmodium falciparum</italic>, and ifosfamide-induced encephalopathy, as well as for diagnostic purposes such as sentinel lymph node mapping during breast procedures and parathyroid gland mapping during parathyroidectomies. This activity will highlight the indications, mechanism of action, adverse event profile, and other key factors pertinent for members of a healthcare team managing patients with methemoglobinemia and related conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Review the indications for the administration of methylene blue.</p></list-item><list-item><p>Identify the potential adverse effects of methylene blue.</p></list-item><list-item><p>Outline the typical presentation of a patient experiencing methemoglobinemia.</p></list-item><list-item><p>Explain the importance of improving care coordination amongst a medical interprofessional team to enhance care coordination for patients receiving methylene blue.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=88827&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=88827">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-88827.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Methylene blue has FDA approval for the treatment of methemoglobinemia, a condition when Fe2+ of hemoglobin gets oxidized to Fe3+, reducing the oxygen-carrying capacity of hemoglobin, and typically presents with cyanosis of the lips and extremities, characteristic "chocolate-colored urine," and hypoxia.<xref ref-type="bibr" rid="article-88827.r1">[1]</xref> Methemoglobinemia results from exposure to certain drugs such as dapsone, a drug indicated for the treatment of <italic toggle="yes">Mycoplasma leprae</italic> and <italic toggle="yes">Pneumocystis jirovecii</italic> prophylaxis, benzocaine (a local anesthetic), high altitude water sources, and nitrites such as nitroglycerin or amyl nitrite used for treating coronary artery disease.<xref ref-type="bibr" rid="article-88827.r1">[1]</xref>&#x000a0;</p>
        <p>The remaining indications are non-FDA approved. The first indication is for vasoplegic syndrome, a type of distributive shock that occurs during coronary procedures (specifically coronary artery bypass grafting) as a means to increase systemic vascular resistance when the use of epinephrine is refractory.<xref ref-type="bibr" rid="article-88827.r2">[2]</xref>&#x000a0;Another indication for methylene blue is during a lumpectomy/mastectomy with sentinel lymph node biopsy, as it is applied as a dye to map out which lymph nodes, if any, have any signs of malignancy.<xref ref-type="bibr" rid="article-88827.r3">[3]</xref>&#x000a0;It can also reduce post-injection pain when used 45 seconds&#x000a0;before the administration of propofol.<xref ref-type="bibr" rid="article-88827.r4">[4]</xref>&#x000a0;Indications for methylene blue also include the treatment of <italic toggle="yes">Plasmodium falciparum</italic> in areas that have shown resistance to chloroquine and pyrimethamine-sulfadoxine.<xref ref-type="bibr" rid="article-88827.r2">[2]</xref>&#x000a0;Methylene blue is also used to treat ifosfamide-induced encephalopathy due to the drug's ability&#x000a0;to prevent the formation of neurotoxic metabolites that cause the encephalopathy.<xref ref-type="bibr" rid="article-88827.r5">[5]</xref><xref ref-type="bibr" rid="article-88827.r6">[6]</xref>&#x000a0;Another indication for the use of methylene blue is to identify the parathyroid glands during parathyroidectomy procedures.<xref ref-type="bibr" rid="article-88827.r7">[7]</xref></p>
      </sec>
      <sec id="article-88827.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>The main mechanism of action of methylene blue is reducing the oxidized form of hemoglobin Fe3+ when in a state of methemoglobinemia to Fe2+. In turn, this will increase the oxygen-binding capacity of hemoglobin and thus increase oxygen delivery to tissues. This property is also exhibited by vitamin C, which is an alternative treatment option for methemoglobinemia. Methylene blue also inhibits the enzymes endothelial nitric oxide synthase (eNOS), inducible nitric oxide synthase (iNOS), and&#x000a0;guanylate cyclase, decreasing the amount of cGMP needed for nitrous oxide to be released, therefore causing vasoconstriction of blood vessels via inhibition of vascular smooth muscle relaxation.<xref ref-type="bibr" rid="article-88827.r2">[2]</xref>&#x000a0;Regarding malaria treatment, methylene blue has been shown to improve the chloroquine response to malaria by decreasing its resistance and inhibiting <italic toggle="yes">Plasmodium falciparum</italic>&#x000a0;glutathione reductase, an enzyme that prevents the formation&#x000a0;of byproducts formed by the <italic toggle="yes">Plasmodium</italic> species that triggers the body's immune response.<xref ref-type="bibr" rid="article-88827.r2">[2]</xref><xref ref-type="bibr" rid="article-88827.r8">[8]</xref></p>
      </sec>
      <sec id="article-88827.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Administration of methylene blue for both children and adults experiencing methemoglobinemia is done intravenously at a dose of 1 mg/kg of a 1% solution over 5&#x000a0;to 30 minutes. When using methylene blue for lymph node mapping, the most common two doses are 2 mL and 5 mL of a 1% solution t given intraparenchymal.<xref ref-type="bibr" rid="article-88827.r3">[3]</xref>&#x000a0;When used to prevent post-injection pain, when used 45 seconds&#x000a0;before propofol administration, the dose is 50 mg given as a 2 mL bolus.<xref ref-type="bibr" rid="article-88827.r4">[4]</xref>&#x000a0;Treating ifosfamide-induced encephalopathy with methylene blue is given intravenously at a dose of 50 mg every 4 hours until asymptomatic.<xref ref-type="bibr" rid="article-88827.r9">[9]</xref>&#x000a0;Methylene blue is also infused for 20 minutes at a dose of 2 mg/kg for a patient experiencing vasoplegic syndrome and may be given pre-operatively and post-operatively to reduce mortality.<xref ref-type="bibr" rid="article-88827.r10">[10]</xref><xref ref-type="bibr" rid="article-88827.r11">[11]</xref>&#x000a0;To identify the parathyroid glands, methylene blue is administered 1 hour before the parathyroidectomy intravenously at a dose of 5 mg/mL.<xref ref-type="bibr" rid="article-88827.r7">[7]</xref>&#x000a0;Treating <italic toggle="yes">Plasmodium falciparum</italic> requires three days of treatment at a dose of &#x000a0;300 to 1000&#x000a0;mg per day in adults and 20&#x02013;300&#x000a0;mg per day in children of methylene blue, given as a supplement.<xref ref-type="bibr" rid="article-88827.r12">[12]</xref></p>
      </sec>
      <sec id="article-88827.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>One of the most common adverse effects of methylene blue is the bluish-green discoloration of urine. Another common adverse effect is limb pain following IV administration. methylene blue may contribute to serotonin syndrome if combined with other serotonergic drugs such as SSRIs, SNRIs, MAOIs, and TCAs due to the MAOI activity that methylene blue has.<xref ref-type="bibr" rid="article-88827.r13">[13]</xref>&#x000a0;Serotonin syndrome increases sympathetic and neuromuscular activity; therefore, symptoms include diaphoresis, clonus, and tremors. In adults, methylene blue can cause central nervous system-related&#x000a0;symptoms such as dizziness, confusion, and headaches.<xref ref-type="bibr" rid="article-88827.r14">[14]</xref>&#x000a0;Administration of methylene blue in neonates has led to hyperbilirubinemia, respiratory depression, pulmonary edema, phototoxicity, and hemolytic anemia.<xref ref-type="bibr" rid="article-88827.r15">[15]</xref><xref ref-type="bibr" rid="article-88827.r16">[16]</xref></p>
      </sec>
      <sec id="article-88827.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Methylene blue is contraindicated&#x000a0;in patients who have demonstrated hypersensitivities or anaphylaxis after past administration and for those with glucose-6-phosphate dehydrogenase deficiency due to susceptibility to experiencing hemolytic anemia. Those experiencing hemolytic anemia in this situation will have jaundice and characteristic Heinz bodies on a peripheral blood smear.<xref ref-type="bibr" rid="article-88827.r17">[17]</xref>&#x000a0;Methylene blue is also contraindicated in pregnant women. The FDA has assigned a pregnancy class X rating for methylene blue due to intestinal atresia and fetal death following an intra-amniotic injection, specifically in the second trimester.<xref ref-type="bibr" rid="article-88827.r18">[18]</xref></p>
      </sec>
      <sec id="article-88827.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Methylene blue is a safe drug&#x000a0;at a therapeutic dose of less than 2 mg/kg; however, when levels are greater than 7 mg/kg, many of the adverse effects it exhibits will occur.<xref ref-type="bibr" rid="article-88827.r2">[2]</xref>&#x000a0;Serotonin syndrome has been found to occur when combining serotonergic agents with methylene blue at a dose of 5 mg/kg.<xref ref-type="bibr" rid="article-88827.r19">[19]</xref>&#x000a0;Methylene blue use also requires caution in patients with renal failure due to its ability to reduce renal blood flow.<xref ref-type="bibr" rid="article-88827.r2">[2]</xref>&#x000a0;Also, as noted in adverse effects, patients taking any drug with serotonergic activity, such as SSRIs, should avoid the administration of methylene blue due to the risk of serotonin syndrome.&#x000a0;</p>
      </sec>
      <sec id="article-88827.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>The research concludes that there has been no antidote for treating methylene blue toxicity to be found to exist. If anaphylaxis does occur, the administration of methylene blue should stop immediately and promptly, followed by supportive care, although severe anaphylactic shock with methylene blue is quite rare. Methylene blue may become potentially fatal when used in combination with medications&#x000a0;that include or increase serotonin; this is because of its monoamine oxidase-inhibiting properties. It may precipitate serotonin toxicity at doses greater than 5 mg/kg.</p>
      </sec>
      <sec id="article-88827.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Clinicians primarily use methylene blue for methemoglobinemia and lymph node mapping during breast surgery; however, &#x000a0;there are other serious life-threatening situations where it can be applied that are considered off-label uses. Understanding and mastering the indications for the use of methylene blue is essential in many potentially life-threatening situations, such as vasoplegic syndrome and ifosfamide-induced encephalopathy, and if not acted upon appropriately and promptly, these disorders could spell disaster for the patient. The entire interprofessional healthcare team, including clinicians, mid-level practitioners, nurses, and pharmacists, must maintain open communication and information sharing to optimize the use of methylene blue for maximum patient benefit. [Level 5]</p>
      </sec>
      <sec id="article-88827.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=88827&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=88827">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/88827/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=88827">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-88827.s11">
        <title>References</title>
        <ref id="article-88827.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>do Nascimento</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Pereira</surname>
                <given-names>RO</given-names>
              </name>
              <name>
                <surname>de Mello</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Costa</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Methemoglobinemia: from diagnosis to treatment.</article-title>
            <source>Rev Bras Anestesiol</source>
            <year>2008</year>
            <season>Nov-Dec</season>
            <volume>58</volume>
            <issue>6</issue>
            <fpage>651</fpage>
            <page-range>651-64</page-range>
            <pub-id pub-id-type="pmid">19082413</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88827.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ginimuge</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Jyothi</surname>
                <given-names>SD</given-names>
              </name>
            </person-group>
            <article-title>Methylene blue: revisited.</article-title>
            <source>J Anaesthesiol Clin Pharmacol</source>
            <year>2010</year>
            <month>Oct</month>
            <volume>26</volume>
            <issue>4</issue>
            <fpage>517</fpage>
            <page-range>517-20</page-range>
            <pub-id pub-id-type="pmid">21547182</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88827.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Qi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Sentinel lymph node biopsy mapped with methylene blue dye alone in patients with breast cancer: A systematic review and meta-analysis.</article-title>
            <source>PLoS One</source>
            <year>2018</year>
            <volume>13</volume>
            <issue>9</issue>
            <fpage>e0204364</fpage>
            <pub-id pub-id-type="pmid">30235340</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88827.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salman</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Salman</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Saricaoglu</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Akinci</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Aypar</surname>
                <given-names>&#x000dc;</given-names>
              </name>
            </person-group>
            <article-title>Pain on injection of propofol: a comparison of methylene blue and lidocaine.</article-title>
            <source>J Clin Anesth</source>
            <year>2011</year>
            <month>Jun</month>
            <volume>23</volume>
            <issue>4</issue>
            <fpage>270</fpage>
            <page-range>270-4</page-range>
            <pub-id pub-id-type="pmid">21663809</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88827.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pelgrims</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>De Vos</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Van den Brande</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schrijvers</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Prov&#x000e9;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vermorken</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature.</article-title>
            <source>Br J Cancer</source>
            <year>2000</year>
            <month>Jan</month>
            <volume>82</volume>
            <issue>2</issue>
            <fpage>291</fpage>
            <page-range>291-4</page-range>
            <pub-id pub-id-type="pmid">10646879</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88827.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ajithkumar</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Parkinson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Shamshad</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Murray</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Ifosfamide encephalopathy.</article-title>
            <source>Clin Oncol (R Coll Radiol)</source>
            <year>2007</year>
            <month>Mar</month>
            <volume>19</volume>
            <issue>2</issue>
            <fpage>108</fpage>
            <page-range>108-14</page-range>
            <pub-id pub-id-type="pmid">17355105</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88827.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dudley</surname>
                <given-names>NE</given-names>
              </name>
            </person-group>
            <article-title>Methylene blue for rapid identification of the parathyroids.</article-title>
            <source>Br Med J</source>
            <year>1971</year>
            <month>Sep</month>
            <day>18</day>
            <volume>3</volume>
            <issue>5776</issue>
            <fpage>680</fpage>
            <page-range>680-1</page-range>
            <pub-id pub-id-type="pmid">5569552</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88827.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Olivier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Van Den Ham</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Shio</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Kassa</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Fougeray</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Malarial pigment hemozoin and the innate inflammatory response.</article-title>
            <source>Front Immunol</source>
            <year>2014</year>
            <volume>5</volume>
            <fpage>25</fpage>
            <pub-id pub-id-type="pmid">24550911</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88827.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>K&#x000fc;pfer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Aeschlimann</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wermuth</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Cerny</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Prophylaxis and reversal of ifosfamide encephalopathy with methylene-blue.</article-title>
            <source>Lancet</source>
            <year>1994</year>
            <month>Mar</month>
            <day>26</day>
            <volume>343</volume>
            <issue>8900</issue>
            <fpage>763</fpage>
            <page-range>763-4</page-range>
            <pub-id pub-id-type="pmid">7510815</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88827.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shanmugam</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Vasoplegic syndrome--the role of methylene blue.</article-title>
            <source>Eur J Cardiothorac Surg</source>
            <year>2005</year>
            <month>Nov</month>
            <volume>28</volume>
            <issue>5</issue>
            <fpage>705</fpage>
            <page-range>705-10</page-range>
            <pub-id pub-id-type="pmid">16143539</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88827.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levin</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Degrange</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Bruno</surname>
                <given-names>GF</given-names>
              </name>
              <name>
                <surname>Del Mazo</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Taborda</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Griotti</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Boullon</surname>
                <given-names>FJ</given-names>
              </name>
            </person-group>
            <article-title>Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery.</article-title>
            <source>Ann Thorac Surg</source>
            <year>2004</year>
            <month>Feb</month>
            <volume>77</volume>
            <issue>2</issue>
            <fpage>496</fpage>
            <page-range>496-9</page-range>
            <pub-id pub-id-type="pmid">14759425</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88827.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meissner</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Mandi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Coulibaly</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Witte</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tapsoba</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mansmann</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Rengelshausen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schiek</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Jahn</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Walter-Sack</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Mikus</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Burhenne</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Riedel</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Schirmer</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Kouyat&#x000e9;</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Methylene blue for malaria in Africa: results from a dose-finding study in combination with chloroquine.</article-title>
            <source>Malar J</source>
            <year>2006</year>
            <month>Oct</month>
            <day>08</day>
            <volume>5</volume>
            <fpage>84</fpage>
            <pub-id pub-id-type="pmid">17026773</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88827.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gillman</surname>
                <given-names>PK</given-names>
              </name>
            </person-group>
            <article-title>CNS toxicity involving methylene blue: the exemplar for understanding and predicting drug interactions that precipitate serotonin toxicity.</article-title>
            <source>J Psychopharmacol</source>
            <year>2011</year>
            <month>Mar</month>
            <volume>25</volume>
            <issue>3</issue>
            <fpage>429</fpage>
            <page-range>429-36</page-range>
            <pub-id pub-id-type="pmid">20142303</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88827.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martindale</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Stedeford</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Neurological sequelae following methylene blue injection for parathyroidectomy.</article-title>
            <source>Anaesthesia</source>
            <year>2003</year>
            <month>Oct</month>
            <volume>58</volume>
            <issue>10</issue>
            <fpage>1041</fpage>
            <page-range>1041-2</page-range>
            <pub-id pub-id-type="pmid">12969068</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88827.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cragan</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Teratogen update: methylene blue.</article-title>
            <source>Teratology</source>
            <year>1999</year>
            <month>Jul</month>
            <volume>60</volume>
            <issue>1</issue>
            <fpage>42</fpage>
            <page-range>42-8</page-range>
            <pub-id pub-id-type="pmid">10413340</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88827.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Crooks</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Haemolytic jaundice in a neonate after intra-amniotic injection of methylene blue.</article-title>
            <source>Arch Dis Child</source>
            <year>1982</year>
            <month>Nov</month>
            <volume>57</volume>
            <issue>11</issue>
            <fpage>872</fpage>
            <page-range>872-3</page-range>
            <pub-id pub-id-type="pmid">6890790</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88827.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Clifton</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Leikin</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Methylene blue.</article-title>
            <source>Am J Ther</source>
            <year>2003</year>
            <season>Jul-Aug</season>
            <volume>10</volume>
            <issue>4</issue>
            <fpage>289</fpage>
            <page-range>289-91</page-range>
            <pub-id pub-id-type="pmid">12845393</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88827.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kidd</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Lancaster</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Boogert</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fisher</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Robertson</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wass</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Fetal death after exposure to methylene blue dye during mid-trimester amniocentesis in twin pregnancy.</article-title>
            <source>Prenat Diagn</source>
            <year>1996</year>
            <month>Jan</month>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>39</fpage>
            <page-range>39-47</page-range>
            <pub-id pub-id-type="pmid">8821851</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88827.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gillman</surname>
                <given-names>PK</given-names>
              </name>
            </person-group>
            <article-title>Methylene blue implicated in potentially fatal serotonin toxicity.</article-title>
            <source>Anaesthesia</source>
            <year>2006</year>
            <month>Oct</month>
            <volume>61</volume>
            <issue>10</issue>
            <fpage>1013</fpage>
            <page-range>1013-4</page-range>
            <pub-id pub-id-type="pmid">16978328</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
